Loading stock data…
Palvella Therapeutics, Inc. (PVLA)
$152.28-4.96 (-3.15%)
Market ClosedLast close Sep 8
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Palvella Therapeutics, Inc. in the Healthcare sector is trading at $152.28 with a market capitalization of $2.2B. Wall Street consensus targets $230.53 (15 analysts), implying a +51.4% move over the next 12 months. The stock is currently near its 52-week high of $161.38, remaining 27.7% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +51.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.41M↓ | -$14.86M↓ | -$11.30M↓ | -$10.18M↓ | -$9.25M |
| Net Income | -$21.87M↓ | -$15.77M↓ | -$12.71M↓ | -$11.35M↓ | -$9.47M |
Peer Comparison
JNJUNHPFE
Fundamentals
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.45%
Volume
Today's trading volume
163,923
Recent News
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity. Chief Financial Officer Tavo Espinoza said Ligand has
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
Palvella (PVLA) Q2 2026 Earnings Call Transcript
Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy.
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?
Palvella Therapeutics stock has delivered a very strong 285.7% return over the past year, yet the latest valuation checks and stretched market multiples suggest the current price may already be baking in a lot of optimism. Palvella Therapeutics has returned 285.7% over the last 12 months, which puts extra focus on whether recent gains are supported by the fundamentals. Progress on the QTORIN rapamycin program, including the rolling New Drug Application and plans for a potential commercial...
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Palvella Therapeutics, Inc.'s Q2 2026 earnings call